SGN19A-001: A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With Relapsed or Refractory B-Lineage Non-Hodgkin
What is the purpose of this study?
This is a phase 1,
open-label, dose-escalation, multicenter study to evaluate the safety and
tolerability of SGN-CD19A in patients with relapsed or refractory B-lineage
non-Hodgkin lymphoma (B-NHL)
Who can participate?
ELIGIBLE FOR STUDY: 12 Years and older
- Pathologically confirmed
diagnosis of mantle cell lymphoma,
follicular lymphoma Grade 3, diffuse large B-cell lymphoma (DLBCL),
including transformed follicular histology, Burkitt lymphoma,
or B-lineage lymphoblastic lymphoma
- Relapsed, refractory, or progressive disease
following at least 1 prior systemic therapy.
Patients with DLBCL or follicular
lymphoma Grade 3 must have also received
intensive salvage therapy.
- Eastern Cooperative Oncology Group status of 0 or 1
- Measurable disease
- Allogeneic stem cell transplant (SCT)
- Cancer - Leukemia and Lymphoma
Will I get all the facts about the study?
Study Type: Interventional
Masking: Open Label
Primary Purpose: Treatment
Who should I contact for more information?
For more information
Hospital Medical Center
Burnet Ave., Cincinnati, OH 45229-3039
Where can I find additional information?